Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Gosav, Evelina Maria; Ouatu, Anca; Bădescu, Magda; Dima, Nicoleta; Ganceanu-Rusu, Ana Roxana; Popescu, Dan; Floria, Mariana; Rezuş, Elena; Rezuş, Ciprian

doi:10.3390/life11101057

Cited by 8 publications

(4 citation statements)

References 181 publications

(207 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism of miRNAs action is based on the inhibition of protein translation process or direct degradation of mRNA of the target genes through binding of miRNAs to the complementary region of the target mRNA molecule [ 130 ]. Much data is available confirming the participation of miRNAs in the process of physiological regulation of the heart function and also in the progression of cardiovascular diseases [ 131 , 132 , 133 , 134 ].…”

Section: Ncrnas As the Modulators Of Lgals3 Gene Expression And A New Potential Therapeutic Targetmentioning

confidence: 99%

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

2021

View full text Add to dashboard Cite

Galectin-3 plays a prominent role in chronic inflammation and has been implicated in the development of many disease conditions, including heart disease. Galectin-3, a regulatory protein, is elevated in both acute and chronic heart failure and is involved in the inflammatory pathway after injury leading to myocardial tissue remodelling. We discussed the potential utility of galectin-3 as a diagnostic and disease severity/prognostic biomarker in different cardio/cerebrovascular diseases, such as acute ischemic stroke, acute coronary syndromes, heart failure and arrhythmogenic cardiomyopathy. Over the last decade there has been a marked increase in the understanding the role of galectin-3 in myocardial fibrosis and inflammation and as a therapeutic target for the treatment of heart failure and myocardial infarction.

show abstract

Section: Ncrnas As the Modulators Of Lgals3 Gene Expression And A New Potential Therapeutic Targetmentioning

confidence: 99%

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

2021

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRNAs) are a class of ncRNAs that regulate gene expression posttranscriptionally (14). These small ncRNAs are single-stranded RNAs, 19-24 nucleotides in length (15). So far, the miRBase data set (version 22) counts 1917 miRNA precursors and 2656 mature miRNAs in humans (16).…”

Section: Biogenesis and Functions Of Mirnasmentioning

confidence: 99%

“…Although primarily localized intracellularly, miRNAs are also detected in extracellular fluids (plasma, serum, cerebrospinal fluid, urine, saliva, breast milk) originating from damaged or living cells (14,15). Considering the availability of blood as a sample, circulating miRNAs are being intensively investigated as potential biomarkers in the diagnosis and prognosis of cardiovascular and other diseases (22).…”

Section: Biogenesis and Functions Of Mirnasmentioning

confidence: 99%

Circulating non-coding RNAs as biomarkers in coronary artery disease

Petković¹,

Erceg²,

Munjas³

et al. 2022

Arhiv za farmaciju

View full text Add to dashboard Cite

Coronary artery disease (CAD) is a leading cause of mortality worldwide. Atherosclerosis involves an interplay of different pathological mechanisms, such as progressive inflammation, abnormal lipid metabolism, and oxidative stress, and as such represents the basic pathological phenomenon underlying CAD. Atherosclerotic plaque narrows the lumen of coronary arteries, creating an ischemic environment for the heart muscle, which finally leads to clinical complications, such as acute myocardial infarction. Currently, there are no biomarkers that could predict plaque stability or major adverse cardiovascular events (MACE). Numerous functional non-coding RNA (ncRNA) species influence basic cellular functions, and as such play a role in the development and progression of CAD. Of these ncRNAs, micro RNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most investigated. Considering that ncRNAs detected in extracellular fluids can originate from different cells, circulating ncRNAs are being intensively investigated as potential biomarkers in the diagnosis and prognosis of CAD. In the following paper, we provide current insights into potential molecular mechanisms by which miRNAs and lncRNAs contribute to the pathology of CAD and discuss their potential role as biomarkers in diagnosis and prognosis of disease.

show abstract

“…It is mainly used in the late stages of the disease when multiple blood vessels are affected or arteries are seriously stenosed ( Su et al, 2020 ). At present, the most widely used traditional biomarkers for diagnosing coronary heart disease, such as creatine kinase MB, B-type brain natriuretic peptide precursors, and high-sensitivity troponin T/I, are affected by age, genetic background, heart-related diseases, drugs, and lifestyle and cannot be used for early diagnosis of acute myocardial infarction nor can they predict the future complications of coronary heart disease ( Raggi et al, 2018 ; Tanase et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

miR-22-3p as a potential biomarker for coronary artery disease based on integrated bioinformatics analysis

Zhang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Coronary artery disease (CAD) is a common cardiovascular disease that has attracted attention worldwide due to its high morbidity and mortality. Recent studies have shown that abnormal microRNA (miRNA) expression is effective in CAD diagnoses and processes. However, the potential relationship between miRNAs and CAD remains unclear.Methods: Microarray datasets GSE105449 and GSE28858 were downloaded directly from the Gene Expression Omnibus (GEO) to identify miRNAs involved in CAD. Target gene prediction and enrichment analyses were performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG).Results: There were nine differentially expressed miRNAs in CAD patients compared to the controls. A total of 352 genes were predicted and subjected to GO analysis, which showed that differentially expressed genes (DEGs) were mainly associated with axon guidance, neuron projection guidance, neuron-to-neuron synapses, and postsynaptic density. According to the KEGG pathway analysis, the most enriched pathways were those involved in transcriptional misregulation in cancer, growth hormone synthesis, secretion and action, endocrine resistance, axon guidance, and Cushing syndrome. Pathway analysis was mainly involved in the HIPPO and prion disease signaling pathways. Furthermore, a competing endogenous RNA (ceRNA) interaction network centered on miR-22-3p revealed eight related transcription factors in the cardiovascular system. The receiver operating characteristic (ROC) curve analysis suggested that miR-22-3p may be a better CAD predictor.Conclusion: The results indicate that miR-22-3p may function in pathophysiological CAD processes. Our study potentiates miR-22-3p as a specific biomarker for diagnosing CAD.

show abstract

Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Cited by 8 publications

References 181 publications

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

Circulating non-coding RNAs as biomarkers in coronary artery disease

miR-22-3p as a potential biomarker for coronary artery disease based on integrated bioinformatics analysis

Contact Info

Product

Resources

About